Pass-Through to Shareholders

The New Jersey Economic Development Authority’s Technology Business Tax Certificate Transfer Program allows unprofitable technology and biotechnology companies to sell their unused net operating losses and research and development tax credits to profitable corporations for at least 80% of their value in cash. This mechanism functions as a non-dilutive financing bridge, enabling emerging ventures to monetize future tax benefits today to fund immediate research, payroll, and facility expansion.

The program, colloquially known as the Net Operating Loss (NOL) Program, represents a cornerstone of the State of New Jersey’s economic strategy to foster a robust innovation ecosystem. For many early-stage companies in the high-tech and life sciences sectors, the primary barrier to growth is not a lack of viable intellectual property but a lack of liquidity. These firms often incur significant expenses during the research and development phase, long before they achieve the profitability required to utilize tax credits or net operating loss carryovers. By facilitating the sale of these tax attributes to established, profitable corporations, the state effectively creates a marketplace for innovation capital that does not require founders to surrender equity or control. This report provides an exhaustive analysis of the program’s statutory foundations, the technical mechanics of the New Jersey R&D tax credit, the administrative guidance provided by the New Jersey Division of Taxation, and the economic impact of these incentives on the Garden State’s business landscape.

The Statutory Framework: The New Jersey Emerging Technology and Biotechnology Financial Assistance Act

The program finds its legal genesis in the “New Jersey Emerging Technology and Biotechnology Financial Assistance Act,” specifically N.J.S.A. 34:1B-7.37 et seq. The New Jersey Legislature recognized that for society to realize the potential rewards of emerging technology and biotechnology research, private industry must have access to sufficient financial resources to transition research discoveries into viable commercial products. The Act was designed to mitigate the perceived risk of investing in new ventures by providing a mechanism for these companies to unlock the value of their tax losses.

The New Jersey Economic Development Authority (NJEDA) is tasked with determining the eligibility of applicant businesses, while the New Jersey Division of Taxation is responsible for certifying the exact value of the tax benefits available for transfer. This dual-agency oversight ensures that the program meets both its economic development objectives and the state’s rigorous tax compliance standards.

Defining the Eligible Industry Segments

Eligibility for the Tax Certificate Transfer Program is strictly limited to companies that fall under the statutory definitions of “Technology Business” or “Biotechnology Business.” These definitions are critical because they exclude general service or manufacturing firms that do not engage in the specific high-innovation activities the state seeks to incentivize.

Industry Category	Statutory Definition and Scope
Technology Business	An emerging corporation with a headquarters or base of operations in New Jersey that owns, has filed for, or has a license to use protected, proprietary intellectual property. The primary business must involve a scientific process, product, or service such as advanced computing, advanced materials, or environmental technology.
Biotechnology Business	A company involved in the fundamental knowledge of biological systems at the macro, molecular, or sub-atomic levels, focused on developing novel products, services, and technologies based on biological insights.

The program further subdivides these categories into specific “priority” fields. Under N.J.S.A. 54:10A-5.24b, these include advanced computing, advanced materials, biotechnology, electronic device technology, environmental technology, and medical device technology. These priority fields are significant because they qualify for an extended R&D tax credit carryforward period—15 years instead of the standard seven years—acknowledging the longer development cycles and higher capital requirements inherent in these sectors.

Detailed Eligibility Criteria for the Selling Business

The NJEDA enforces a rigorous set of criteria to ensure that participants are truly New Jersey-based innovation firms that contribute to the state’s workforce and economic health. A failure to meet any of these requirements at the time of application or at the time of closing will result in disqualification.

The Unprofitability Test

The core requirement of the program is that the applicant must be unprofitable. Specifically, the business must not have demonstrated positive net operating income on either of its last two full-year income statements as determined by Generally Accepted Accounting Principles (GAAP). This test is not limited to the applicant entity itself; it also applies to any parent company that owns or controls at least 50% of the applicant, as well as any consolidated group of affiliated corporations of which the applicant is a member.

US and New Jersey Employment Thresholds

The program targets “small” and “expanding” companies. The first threshold is that the applicant, including all subsidiaries and parent companies, must have fewer than 225 full-time employees in the United States.

The second threshold relates to the company’s physical presence in New Jersey. The applicant must employ a minimum number of full-time workers who are physically located in New Jersey at least 80% of the time. The required headcount scales with the age of the company to ensure that as a firm grows, its commitment to the New Jersey labor market also grows.

Company Age (since formation)	Minimum NJ Full-Time Employees
Less than 3 years	At least 1 full-time employee
3 to 5 years	At least 5 full-time employees
More than 5 years	At least 10 full-time employees

A “full-time employee” is defined as a person employed for at least 35 hours per week in a permanent or indefinite position. A crucial nuance in the local guidance is the “Pennsylvania exclusion.” Under the reciprocal tax agreement between New Jersey and Pennsylvania, Pennsylvania residents working in New Jersey are not subject to New Jersey Gross Income Tax. Therefore, for the purposes of the NJEDA Tax Certificate Transfer Program, Pennsylvania residents do not count toward the minimum New Jersey full-time employee requirement.

Intellectual Property (IP) Standards

An eligible company must own, have filed for, or have a license to use “Protected Proprietary Intellectual Property” (PPIP). The state defines this as a patent or a registered copyright. If the IP is licensed, the license must be an exclusive license that grants the applicant control over the technology’s development. Non-exclusive licenses, trademarks, and unregistered copyrights are explicitly excluded from the definition of PPIP.

The New Jersey R&D Tax Credit (N.J.S.A. 54:10A-5.24)

While the NJEDA manages the transfer program, the underlying asset being sold is often the New Jersey Research and Development Tax Credit. This credit is governed by N.J.S.A. 54:10A-5.24 and administered by the New Jersey Division of Taxation.

Calculation and Components

The New Jersey R&D tax credit is modeled after the federal credit for increasing research activities found in Internal Revenue Code (IRC) Section 41. However, it is restricted solely to qualified research conducted within New Jersey. The credit is the sum of two distinct calculations:

1. Qualified Research Expenses (QRE) Component: 10% of the excess of the current year’s New Jersey QREs over the “base amount”.
2. Basic Research Component: 10% of the basic research payments made to qualified organizations, such as New Jersey universities or scientific research organizations.

Selection of Calculation Method

Since 2018, the Division of Taxation has required taxpayers to use the same method for the New Jersey credit as they used for their federal Form 6765. This means that if a company uses the “Regular Method” for federal purposes, they must use it for New Jersey; if they use the “Alternative Simplified Credit” (ASC) method federally, they must use the ASC method for New Jersey.

Component	Regular Method Description	ASC Method Description
Base Amount	Fixed-base percentage (ratio of historical QREs to gross receipts) multiplied by the average gross receipts for the prior four years.	One-sixth of the total New Jersey QREs over the prior three taxable years.
Incremental Benefit	Rewards growth relative to a historical baseline.	Ideal for startups with little historical data or fluctuating R&D spend.

The mathematical formula for the New Jersey credit, utilizing the ASC method for an emerging business, is typically expressed as:

Credit = 0.10 * (Current_Year_QREs – (Sum of Prior_Year_QREs / 6)) + 0.10 * Basic_Research_Payments

Qualified Research Expenditures (QREs)

Under the guidance provided in Technical Bulletin TB-114, only specific categories of spending qualify for the New Jersey credit. These expenditures must be linked to research conducted in-state:

• Wages: Salaries for employees directly performing, supervising, or supporting qualified research in New Jersey.
• Supplies: Tangible materials consumed in the research process, such as lab chemicals or testing prototypes.
• Contract Research: 65% of the payments made to third-party consultants or research organizations for qualified services performed in New Jersey.
• Basic Research Payments: Cash contributions to New Jersey universities or scientific research entities for fundamental research.
• Computer Leasing: Costs for leasing computers used directly in New Jersey research activities.

Local State Revenue Office Guidance: The Division of Taxation’s Role

The New Jersey Division of Taxation provides critical technical guidance on the claiming and valuation of these credits. This guidance is primarily disseminated through Technical Bulletins and instructions for corporate business tax (CBT) forms.

Technical Bulletin TB-114: R&D Credit Specifics

Revised in November 2025, TB-114 is the definitive guide for the New Jersey R&D credit. It clarifies that the credit is available to all CBT taxpayers, including C-corporations, S-corporations, and corporate partners in partnerships. Key points from TB-114 include:

• Double-Dipping Prohibition: Taxpayers are strictly prohibited from using the same expenses to calculate both the R&D credit and other New Jersey credits, such as the Manufacturing Equipment and Employment Investment Tax Credit or the Angel Investor Tax Credit.
• Order of Priority: The R&D credit must be applied in a specific order of priority relative to other credits, as prescribed by the Director of the Division of Taxation.
• Minimum Tax Limitation: The R&D credit cannot reduce the taxpayer’s CBT liability below the statutory minimum tax ($500 or $2,000, depending on New Jersey gross receipts).
• Carryover Tracking: Unused credits can be carried forward for seven years for general businesses and 15 years for the high-tech priority industries mentioned earlier.

Form 306 and Filing Deadlines

To claim the R&D credit and participate in the transfer program, a company must file Form 306 (“Research and Development Tax Credit”) with its annual CBT return. A copy of the federal Form 6765 must be attached to the state return.

The Division of Taxation emphasizes a “strict compliance” approach to deadlines. The application for the Tax Certificate Transfer Program must be submitted to the NJEDA by June 30 of each year. Crucially, the company’s CBT return, including Form 306, must also be filed with the Division of Taxation by the same June 30 deadline. Filing an extension for the CBT return does not extend the deadline for the program application. Failure to file the return by June 30 results in the company having no available tax benefit to sell for that program cycle.

Guidance for Combined Groups (TB-90 and TB-95)

With the introduction of mandatory combined reporting in 2019, the Division of Taxation issued TB-90 and TB-95 to explain how tax attributes like R&D credits and NOLs are treated within a unitary business group.

• Sharing vs. Selling: Members of a combined group filing a Form CBT-100U may share tax credits with other taxable members of the same group without needing a Benefit Transfer Certificate. The decision to share a credit lies with the member that generated it.
• External Transfers: Any transfer of credits to an entity outside the combined group must proceed through the NJEDA’s formal Benefit Transfer Program.
• Arm’s-Length Pricing: If a member of a combined group sells its Prior Net Operating Loss (PNOL) conversion carryover to another member of the same group, the sale must be made at an arm’s-length price, as if the sale were to an unrelated taxpayer, and the parties must still meet the eligibility requirements of the program.

The Application and Closing Process: A Procedural Overview

The journey from an unprofitable startup to receiving a cash infusion via the Tax Certificate Transfer Program is a complex, multi-stage administrative lifecycle.

Stage 1: The Annual Application Cycle

The program operates on an annual cycle with a hard deadline of June 30. Applicants must submit an online application through the NJEDA portal along with a non-refundable $1,000 application fee. Documentation required at this stage includes:

• Two years of CPA-prepared financial statements (audited, reviewed, or compiled).
• Evidence of Protected Proprietary Intellectual Property.
• The “Spending Certification Form” (for returning applicants) certifying that previous program proceeds were used for allowable expenditures.

Stage 2: Eligibility and Valuation Review

Following the June 30 deadline, the NJEDA reviews applications for statutory eligibility. Simultaneously, the Division of Taxation reviews the applicant’s tax filings to certify the value of the available NOLs and R&D credits. Because the program is subject to an annual funding cap of $75 million, if the total certified benefits exceed this amount, individual awards are prorated. Of the $75 million, $15 million is specifically set aside for companies in Innovation Zones (Newark, Camden, New Brunswick), Opportunity Zones, or certified minority/woman-owned businesses.

Stage 3: The Benefit Sale and Closing

Once an award is approved, the selling business must identify a “buying business.” The buyer must be a profitable New Jersey corporate taxpayer and cannot be an affiliate of the seller. The NJEDA maintains a courtesy list of potential buyers to facilitate this marketplace.

The exchange of funds must occur for at least 80% of the tax benefit’s face value. Historically, these credits have traded at a market price between 88 and 94 cents on the dollar.

The “Steps to Closing” involve several critical documents:

1. Agreement: The legal contract between the buyer and seller.
2. Selling Business Tax Benefit Identification Form: Specifies which credits/losses are being sold.
3. Private Financial Assistance Form: Details the consideration paid by the buyer.
4. Tax Clearance Certificates: Both the buyer and seller must provide current Tax Clearance Certificates from the Division of Taxation to prove they are in good standing.
5. Approval Fee: For awards over $100,000, the seller must pay an approval fee of 1% of the award (up to a $20,000 total cap, including the initial application fee).

Practical Case Study: NeuroTech Innovations NJ

To illustrate the program’s mechanics, consider “NeuroTech Innovations NJ,” a biotechnology startup founded four years ago and based in Newark (an Innovation Zone).

Step 1: Calculating the Asset

In 2024, NeuroTech Innovations NJ conducted significant research on medical devices. They used the ASC method for their federal and state returns.

Financial Data:

• Current Year NJ QREs: $2,000,000.
• Total NJ QREs (2021-2023): $1,200,000.
• Unused R&D Carryforward (Prior Years): $400,000.

The R&D Credit Calculation (Form 306):

1. Base Amount: $1,200,000 / 6 = $200,000.
2. Excess QREs: $2,000,000 – $200,000 = $1,800,000.
3. Current Year Credit: 10% of $1,800,000 = $180,000.
4. Total Asset: $180,000 (Current) + $400,000 (Carryforward) = $580,000.

Step 2: The Monetization Event

NeuroTech Innovations NJ applies for the program by June 30, 2025. They are approved for the full $580,000. They find a profitable buyer (e.g., a major utility company) willing to pay 91 cents on the dollar.

The Transaction:

• Total Award: $580,000.
• Approval Fee: 1% of $580,000 = $5,800. (Minus $1,000 application fee = $4,800 remaining).
• Sale Price: $580,000 * 0.91 = $527,800.

NeuroTech Innovations NJ receives $527,800 in cash. They use this capital for “Allowable Expenditures,” specifically to hire three more research scientists and upgrade their laboratory equipment.

Post-Closing Obligations and Recapture Provisions

The cash received from the program is not a no-strings-attached grant; it is an investment by the state in the company’s long-term presence in New Jersey.

Allowable Expenditures

The proceeds from the sale must be used for costs incurred in connection with the operation of the technology or biotechnology business in New Jersey. Under N.J.A.C. 19:31K-1.2, these include:

• Expenses of fixed assets (construction, acquisition, and development of real estate).
• Materials and start-up costs.
• Working capital and salaries.
• Funding continued research and development.

The Five-Year Maintenance Requirement

The seller must maintain its headquarters or a base of operations in New Jersey for five years after receiving the benefits. If the company moves out of the state or ceases operations, the NJEDA and the Division of Taxation will invoke the recapture provisions.

The seller must pay back the “face value” of the Tax Certificate (the $580,000 in the example above, not the $527,800 received) according to a sliding scale:

Time of Departure (Post-Closing)	Recapture Percentage
Within 1 Year	100% Payback
Within 2 Years	80% Payback
Within 3 Years	60% Payback
Within 4 Years	40% Payback
Within 5 Years	20% Payback

Crucially, the law protects the buyer of the tax credits. The recapture is only from the initial recipient (the seller), not the purchaser or assignee of the tax credit transfer certificate.

Economic Impact and Strategic Significance

The Tax Certificate Transfer Program is widely regarded as a “lifeline” for New Jersey’s innovation economy. A 2024 independent report highlighted the massive impact the program has had since its launch in 1999.

Metric	Program Outcome (Since Inception)
Total Companies Supported	589
Total Jobs Supported	Over 31,000
Economic Impact (2024)	$28.1 Billion
Survival Rate	72% (vs. 36% industry benchmark)
State Revenue ROI	$2 in tax revenue for every $1 in credits issued

The program’s success stems from its alignment with the specific lifecycle of technology and life sciences startups. By allowing companies to obtain cash without sacrificing equity, the state helps these businesses cross the “valley of death”—the period between early research and market commercialization.

Final Thoughts: Navigating the Intersection of Tax Law and Innovation

The NJEDA Tax Certificate Transfer Program, in its synergy with the New Jersey R&D Tax Credit, represents a sophisticated fiscal tool that transforms theoretical tax benefits into practical innovation capital. For an emerging technology or biotechnology firm in New Jersey, the program offers a non-dilutive path to liquidity that is almost unparalleled in other states. However, the program’s complexity—spanning GAAP-compliant financial reporting, strict employment minimums physically verified in New Jersey, and the rigid June 30 filing deadline—requires a high degree of administrative discipline.

Local guidance from the New Jersey Division of Taxation, particularly concerning the exclusion of Pennsylvania residents and the mandated alignment with federal R&D credit calculation methods, adds layers of technicality that businesses must navigate with precision. For profitable corporate buyers, the program offers a risk-mitigated way to reduce state tax liabilities at a discount, while simultaneously supporting the local innovation ecosystem. As New Jersey continues to expand these programs, such as through the 2020 Economic Recovery Act’s increase in caps, the Tax Certificate Transfer Program remains a vital bridge for the next generation of life-saving medical devices, advanced materials, and environmental technologies. Businesses looking to leverage these incentives must adopt a proactive, year-round strategy for R&D documentation and financial compliance to ensure they are positioned to capture the full value of their innovation assets.